Biocon Q3FY26 Revenue at ₹4,173 Cr, Net Profit ₹144 Cr
Biocon Limited reported Q3FY26 operating revenue of ₹4,173 crore, up 9% YoY. EBITDA increased 21% to ₹951 crore, and Net Profit surged 475% to ₹144 crore. The company fully integrated Biocon Biologics for approximately USD 5.5 billion and raised nearly USD 1 billion through two QIPs. Credit ratings for Biocon Biologics were upgraded.
The financial results show significant growth across key metrics. The full integration of Biocon Biologics and substantial fundraising through QIPs are major strategic moves that are expected to have a substantial long-term impact on the company's structure, financial leverage, and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and net profit. Key strategic actions like the full integration of Biocon Biologics and successful QIPs, along with credit rating upgrades, indicate positive financial health and investor confidence.
Biocon Limited announced its consolidated financial results for the fiscal third quarter ended December 31, 2025. The company reported an operating revenue of ₹4,173 crore, an increase of 9% year-on-year. EBITDA for the quarter stood at ₹951 crore, up 21% YoY, with an EBITDA margin of 22%. Profit Before Tax (before exceptional items) was ₹226 crore, a 64% increase, and the reported Net Profit for the quarter was ₹144 crore, up 475% YoY.
The Biosimilars segment revenue was ₹2,497 crore, up 9% YoY, with EBITDA at ₹700 crore. The Generics segment reported revenue of ₹851 crore, up 24% YoY. The CRDMO (formerly Research Services) segment revenue was ₹917 crore, a decrease of 3% YoY.
Biocon Limited has also fully integrated Biocon Biologics Limited as a wholly owned subsidiary, a transaction valued at approximately USD 5.5 billion. In January 2026, the company raised ₹4,150 crore (~USD 460 million) through a Qualified Institutions Placement (QIP), marking its second equity issuance within eight months, cumulatively raising nearly USD 1 billion. S&P Global Ratings upgraded Biocon Biologics’ credit rating to BB+ with a ‘Stable’ outlook, and Fitch Ratings revised its outlook to ‘Positive’.
The management will host an Earnings Call on February 13, 2026, at 9:00 AM IST.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.